Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes

Table 2

Phase 3 trials of idiotype vaccines.

Author/Sponsor	Idiotype	Comparison	Pretreatment	Patient status prevaccination	End Point	Results
Levy et al. [118] Genitope	Recombinant	2/1 randomization in first line	8 cycles of CVP	First CR or PR	PFS	𝑃=n.s
Freedman et al. [119] Favrille	Recombinant	2/1 randomization in first line	4 doses of Rituximab	First CR, PR or SD	TTP	𝑃=n.s
Schuster et al. [120] Biovest	From hybridoma	2/1 randomization in first line	6 cycles of PACE or CHOP-R	Firsr CR or CRu	DFS	𝑃=.045